GREENWAY TECHNOLOGIES, INC. & SUBSIDIARIES — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that GREENWAY TECHNOLOGIES, INC. & SUBSIDIARIES filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $24.6K | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $15.5K | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $59.3K | Apr 14, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | ($30.1K) | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | ($80.9K) | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $27.0K | Apr 14, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.96M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($1.51M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($1.58M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($1.51M) | Jul 16, 2024 |
| FY2022 | Dec 31, 2021 | ($1.74M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($2.54M) | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | ($3.66M) | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | ($3.19M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($9.15M) | May 13, 2019 |
| FY2018 | Dec 31, 2016 | ($2.02M) | May 13, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.69M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($894.3K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($960.7K) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($942.9K) | Jul 16, 2024 |
| FY2022 | Dec 31, 2021 | ($1.12M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($1.37M) | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | ($2.43M) | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | ($2.89M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($9.13M) | May 13, 2019 |
| FY2017 | Dec 31, 2016 | ($2.02M) | Apr 16, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.21M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $50.0K | Apr 15, 2026 |
| FY2023 | Dec 31, 2022 | $54.3K | Jul 16, 2024 |
| FY2022 | Dec 31, 2021 | $158.0K | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $30.0K | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | $441.3K | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $630.5K | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $867.1K | May 13, 2019 |
| FY2017 | Dec 31, 2016 | $967.3K | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | $766.7K | Apr 17, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($710.3K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($444.2K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($302.7K) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($496.7K) | Jul 16, 2024 |
| FY2022 | Dec 31, 2021 | ($791.9K) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($686.0K) | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | ($1.30M) | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | ($1.29M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($2.23M) | May 13, 2019 |
| FY2017 | Dec 31, 2016 | ($1.85M) | Apr 16, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $0 | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | ($59.2K) | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | ($2.0K) | Apr 14, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.8K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $20.3K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $1.1K | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $27.5K | Jul 16, 2024 |
| FY2022 | Dec 31, 2021 | $60.6K | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $12.9K | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | $428.9K | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $88.2K | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $269.0K | May 13, 2019 |
| FY2017 | Dec 31, 2016 | $86.8K | Apr 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $9.95M | Apr 11, 2022 |
| FY2021 | Dec 31, 2020 | $8.86M | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | $7.32M | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $4.78M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $3.08M | May 13, 2019 |
| FY2017 | Dec 31, 2016 | $2.50M | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | $2.27M | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | $4.34M | Apr 18, 2016 |
| FY2014 | Dec 31, 2013 | $3.37M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $3.01M | Apr 14, 2014 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.08M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($13.01M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | ($12.03M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | ($10.74M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | ($9.89M) | Jul 16, 2024 |
| FY2022 | Dec 31, 2020 | ($8.84M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2019 | ($6.89M) | Apr 11, 2022 |
| FY2020 | Dec 31, 2018 | ($4.69M) | Apr 14, 2021 |
| FY2019 | Dec 31, 2017 | ($2.81M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2016 | ($2.42M) | May 13, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($41.33M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($39.37M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($37.86M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($36.28M) | Jul 16, 2024 |
| FY2022 | Dec 31, 2021 | ($34.77M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($33.02M) | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | ($30.48M) | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | ($26.82M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($23.62M) | May 13, 2019 |
| FY2017 | Dec 31, 2016 | ($14.48M) | Apr 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.1K | Jul 16, 2024 |
| FY2023 | Dec 31, 2022 | $24.6K | Jul 16, 2024 |
| FY2022 | Dec 31, 2021 | $60.5K | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.6K | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | $16.0K | Apr 14, 2021 |
| FY2016 | Dec 31, 2016 | $68.0K | Apr 17, 2017 |
| FY2016 | Dec 31, 2015 | $0 | Apr 17, 2017 |
| FY2016 | Dec 31, 2014 | $77.5K | Apr 17, 2017 |
| FY2015 | Dec 31, 2013 | $95 | Apr 18, 2016 |
| FY2014 | Dec 31, 2012 | $194.4K | Mar 31, 2015 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $1.25M | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $1.37M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $1.09M | Apr 14, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Jul 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 14, 2023 |
| FY2016 | Dec 31, 2016 | 0 | Apr 17, 2017 |
| FY2016 | Dec 31, 2015 | 0 | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Apr 18, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Jul 16, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 456.36M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 430.84M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 403.84M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | 382.61M | Jul 16, 2024 |
| FY2022 | Dec 31, 2021 | 355.06M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | 335.27M | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | 296.65M | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | 286.70M | Apr 14, 2020 |
| FY2016 | Dec 31, 2016 | 126,938 | Apr 17, 2017 |
| FY2016 | Dec 31, 2015 | 15.13M | Apr 17, 2017 |